In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)

Relebactam (formerly MK-7655) is an inhibitor of class A and C β-lactamases, including Klebsiella pneumoniae carbapenemase (KPC), and is currently in clinical development in combination with imipenem-cilastatin. Using Clinical and Laboratory Standards Institute (CLSI)-defined broth microdilution met...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Lob, Sibylle H., Hackel, Meredith A., Kazmierczak, Krystyna M., Young, Katherine, Motyl, Mary R., Karlowsky, James A., Sahm, Daniel F.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2017
Sujets:
Susceptibility
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5444184/
https://ncbi.nlm.nih.gov/pubmed/28320716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02209-16
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires